Related changes
Jump to navigation
Jump to search
Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
10 May 2024
|
|
19:11 | Sotagliflozin 5 changes history +3,623 [Alen Antony (5×)] | |||
|
|
19:11 (cur | prev) +829 Alen Antony talk contribs | ||||
|
|
18:12 (cur | prev) +833 Alen Antony talk contribs | ||||
|
|
17:54 (cur | prev) +545 Alen Antony talk contribs | ||||
|
|
17:46 (cur | prev) +744 Alen Antony talk contribs | ||||
|
|
17:12 (cur | prev) +672 Alen Antony talk contribs | ||||
9 May 2024
|
|
N 23:59 | Sotagliflozin 3 changes history +1,667 [Alen Antony (3×)] | |||
|
|
23:59 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
15:17 (cur | prev) +1,230 Alen Antony talk contribs | ||||
| N |
|
04:57 (cur | prev) +418 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}") | |||